Can tumor mutational burden determine the most effective treatment for lung cancer patients?

Lung Cancer Manag. 2020 Jan 14;8(4):LMT21. doi: 10.2217/lmt-2019-0013.

Authors

Shixiang Wang¹, Zaoke He¹, Xuan Wang¹, Huimin Li¹, Tao Wu¹, Xiaoqin Sun¹, Kai Wu², Xue-Song Liu¹

Affiliations

¹ School of Life Science & Technology, ShanghaiTech University, Shanghai 201203, China.
² Department of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Abstract

formula image

Keywords: TMB; biomarker; cancer immunotherapy; immune checkpoint inhibitor; lung cancer; tumor mutational burden.

Publication types

Editorial